Your browser doesn't support javascript.
loading
Human Metastatic Cholangiocarcinoma Patient-Derived Xenografts and Tumoroids for Preclinical Drug Evaluation.
Serra-Camprubí, Queralt; Verdaguer, Helena; Oliveros, Winona; Lupión-Garcia, Núria; Llop-Guevara, Alba; Molina, Cristina; Vila-Casadesús, Maria; Turpin, Anthony; Neuzillet, Cindy; Frigola, Joan; Querol, Jessica; Yáñez-Bartolomé, Mariana; Castet, Florian; Fabregat-Franco, Carles; Escudero-Iriarte, Carmen; Escorihuela, Marta; Arenas, Enrique J; Bernadó-Morales, Cristina; Haro, Noemí; Giles, Francis J; Pozo, Óscar J; Miquel, Josep M; Nuciforo, Paolo G; Vivancos, Ana; Melé, Marta; Serra, Violeta; Arribas, Joaquín; Tabernero, Josep; Peiró, Sandra; Macarulla, Teresa; Tian, Tian V.
Afiliación
  • Serra-Camprubí Q; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Verdaguer H; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Oliveros W; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Lupión-Garcia N; Life Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain.
  • Llop-Guevara A; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Molina C; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Vila-Casadesús M; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Turpin A; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Neuzillet C; Université de Lille, CNRS INSERM UMR9020-U1277, CANTHER Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France.
  • Frigola J; Medical Oncology Department, CHRU Lille, Lille, France.
  • Querol J; Gastrointestinal Oncology, Medical Oncology Department, Curie Institute, Versailles St-Quentin-Paris Saclay University, Saint-Cloud, France.
  • Yáñez-Bartolomé M; Clinical Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Castet F; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Fabregat-Franco C; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Escudero-Iriarte C; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Escorihuela M; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Arenas EJ; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Bernadó-Morales C; Gastrointestinal and Endocrine Tumor Unit, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
  • Haro N; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Giles FJ; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Pozo ÓJ; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Miquel JM; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Nuciforo PG; Neurosciences Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Vivancos A; Developmental Therapeutics Consortium, Chicago, Illinois.
  • Melé M; Neurosciences Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.
  • Serra V; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Arribas J; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Tabernero J; Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Peiró S; Life Sciences Department, Barcelona Supercomputing Center (BSC), Barcelona, Spain.
  • Macarulla T; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Tian TV; Preclinical and Translational Research Program, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
Clin Cancer Res ; 29(2): 432-445, 2023 01 17.
Article en En | MEDLINE | ID: mdl-36374558
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Colangiocarcinoma Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de los Conductos Biliares / Colangiocarcinoma Tipo de estudio: Guideline / Prognostic_studies Límite: Humans Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Estados Unidos